L&K Biomed Signs U.S. Sales Deal with Medtronic for Largest Market
Predicted impact: Medium
US sales deal with Medtronic for a small company; value not disclosed, revenue only ₩40B.
L&K Biomed엘앤케이바이오
156100 · KOSDAQ · ₩156100 · 엘앤케이바이오
₩7,180▲ ₩380 (5.59%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −24.18%
- Market cap
- ₩160B
- Enterprise value
- ₩166B
- P/E
- 58.0×
- P/B
- 2.5×
- Dividend yield
- 0.0%
- ROE
- 4.3%
- Net margin
- 6.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−56.2% from the high
₩2,730Today: ₩6,810 – ₩7,270₩16,400
Returns
- 1W+7.5%
- 1M+19.9%
- 3M+84.3%
- 6M−5.7%
- YTD−44.6%
- 1Y−24.2%
- Volume today
- 379,477
- 1.7× the 20-day average
- Traded today
- ₩2.7B
- Listed shares
- 22,351,153
- EPS (12 months)
- ₩124
- Earnings yield 1.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.6% on Oct 28, 2026. Trading value 1.9× its normal.
L&K Biomed has signed a U.S. sales deal with Medtronic, according to a Money Today report. The report points to this as a deal for the company's largest market.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors bought a net ₩276M that day
- • Buzz 55 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Normal- BuzzNormalBuzz 55: heavy trading.
- SentimentPositiveNews: A new U.S. sales deal with a large medical device firm is a positive headline. Community: 0 bullish, 0 bearish posts this week.
- MomentumStrong21.5% over the last month; the price is above its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
L&K Biomed stock overview
L&K Biomed (엘앤케이바이오, KRX: 156100) is listed on KOSDAQ, in the Medical & precision devices sector. The company designs, develops, manufactures and sells spinal fixation devices and other spine surgery products, mainly used by orthopedic and neurosurgery specialists. Its shares closed at ₩7,180 on Oct 28, 2026, up 5.59% on the day, giving it a market value of ₩160B.
Key facts
- Market cap
- ₩160B
- Sector
- Medical & precision devices
- Latest price change
- +5.59%
- As of
- Oct 28, 2026
- Main business
- The company designs, develops, manufactures and sells spinal fixation devices and other spine surgery products, mainly used by orthopedic and neurosurgery specialists.
Quick answers about L&K Biomed
- What does L&K Biomed do?
- The company designs, develops, manufactures and sells spinal fixation devices and other spine surgery products, mainly used by orthopedic and neurosurgery specialists. Its core product lines are Thoraco-Lumbar and Cervical implants, which include cages, screws, rods and plates, and it also sells some complementary surgical products. Its sales are overwhelmingly overseas, with most overseas revenue coming from the Americas, and it also has a smaller domestic presence in Korea.
- What is the market cap of L&K Biomed?
- The market capitalisation of L&K Biomed was ₩160B at the close on Oct 28, 2026.
- Who are the largest shareholders of L&K Biomed?
- According to the latest official filings, the largest reported holders are Kang Guk-jin (12.31%, as of Oct 16, 2026); Tiger Asset Management Discretionary Investment (4.41%, as of Nov 13, 2025); National Pension Service (0.32%, as of Dec 31, 2023).
- When is the next earnings report from L&K Biomed?
- Korean companies rarely announce results dates in advance. Based on when L&K Biomed filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own L&K Biomed?
- Yes. The National Pension Service held 0.32% of L&K Biomed shares as of Dec 31, 2023.
Company profile
The company designs, develops, manufactures and sells spinal fixation devices and other spine surgery products, mainly used by orthopedic and neurosurgery specialists. Its core product lines are Thoraco-Lumbar and Cervical implants, which include cages, screws, rods and plates, and it also sells some complementary surgical products. Its sales are overwhelmingly overseas, with most overseas revenue coming from the Americas, and it also has a smaller domestic presence in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 엘앤케이바이오
- Themes
- Medical devices
- CEO
- 강국진(단독대표)
- Founded
- Dec 2008
- Listed
- Nov 2016
- Listed shares
- 22,351,153
- Fiscal year ends
- Month 12
- Website
- www.lnkbiomed.com
Similar companies
- TSE131290 · ₩3T₩275,000+5.77%
- Kctech281820 · ₩1.9T₩95,500+3.92%
- Classys214150 · ₩1.8T₩27,000+1.89%
- Park Systems140860 · ₩1.6T₩229,500+1.77%
- DI003160 · ₩1.2T₩43,300+14.55%
- LivsMed491000 · ₩1.1T₩43,650+17.65%
- Curiox Biosystems445680 · ₩1.1T₩62,400+0.16%
- Seers458870 · ₩943B₩24,600−6.46%
Recent news
L&K Biomed Attends World's Largest Spine International Conference… "Global Business Collaboration on Track"
Predicted impact: Low
Conference attendance with no quantified business impact.
Recent filings
See all- 5%+ holding reportOct 16, 2026
- Amended: Half-year report (Jun 2026)Sep 30, 2026
- Adjustment of Conversion PriceSep 9, 2026
- Decision on Guarantee of Debt for Another PartyAug 24, 2026
- Insider shareholding reportAug 20, 2026
Titles in Korean until English translations are added.
Also known as: L&K Biomed / 엘앤케이바이오 / 156100 / KRX:156100
Source: KRX statistical information